The aim of this study was to evaluate why high levels of antispermatozoa autoantibodies (SPZAA) in seminal fluid represent a particularly detrimental factor in male fertility. We studied a population of 219 patients consulting us on conjugal sterility associated with an initial asthenospermia. We looked in each case for the presence of SPZAA at the surface of spermatozoa in the seminal fluid and in the serum. We found 31 patients positive for surface SPZAA, 26 of whom had urogenital infections. We also demonstrated statistically significant correlations between high levels of SPZAA in seminal fluid and both a reduction in ejaculate volume and a tendency to oligo-spermia. A similar correlation was found between the reduction in ejaculate volume and oligospermia. These results suggest that urogenital infection is at present the main cause of SPZAA production, that testicular damage is frequently associated with apparently isolated glandular damage, and above all that a high level of SPZAA in seminal fluid has a more detrimental effect on male fertility due to more severe genital (glandular and testicular) damage.

Keywords:
Antispermatozoa autoantibodies, Genital infection, Sterility, male
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.